Section 1 Short title
This Act may be cited as the “Speeding Access to Already Approved Pharmaceuticals Act of 2017”.
Speeding Access to Already Approved Pharmaceuticals Act of 2017
A BILL
To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.
Sec. 2 Expedited review of EU-approved pharmaceuticals
Section 506 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356) is amended by adding at the end the following:
“(i) EU-Approved pharmaceuticals
“(1) Expedited review—Beginning not later than 90 days after a new pharmaceutical is approved for marketing in the European Union, the Secretary shall, at the request of the sponsor of the pharmaceutical, facilitate the development and expedite the review of such new pharmaceutical under section 505 or 515 of this Act or section 351 of the Public Health Service Act, as appropriate.
“(2) Definition—In this subsection, the term pharmaceutical means a drug (including a biological product) or a device.”